Pune-based vaccine maker Gennova could become the second company in India to receive advance payment from the Union government for manufacturing and stockpiling its Covid-19 vaccine, based on mRNA platform, that has shown encouraging results in Phase 1 trials.

Importantly, the manufacturer which is set to apply to the apex drug regulator to begin Phase 2 and 3 trials, is also tailoring the vaccine specifically against the delta variant of the Covid virus, which caused the devastating second wave in India.

Leave a Reply

Your email address will not be published. Required fields are marked *